QUEBEC CITY, April 30, 2015 /PRNewswire/ - DiagnoCure Inc. (TSX: CUR) (OTCQX: DGCRF) (the "Corporation") today announced that its shareholders have approved all resolutions presented to them in the Management Proxy Circular dated March 5, 2015 and put forth for vote during the shareholders meeting held today in Montreal.
Shareholders re-elected Dr. Yves Fradet, Dr. Louise Proulx, Mr. Andrew Sheldon, Dr. Jacques Simoneau, and Dr. Vincent R. Zurawski as directors of the Corporation.
This year, 57.85% of the shares were voted and the results for the nominees as directors are as follows:
|
Nominees
|
Shares For
|
For (%)
|
Shares
Withheld
|
Withheld (%)
|
Non-votes
|
|
Yves Fradet
|
20,334,619
|
93.34
|
1,449,871
|
6.66
|
3,113,479
|
|
Louise Proulx
|
20,336,619
|
93.35
|
1,447,871
|
6.65
|
3,113,479
|
|
Andrew J. Sheldon
|
20,336,119
|
93.35
|
1,448,371
|
6.65
|
3,113,479
|
|
Jacques Simoneau
|
20,396,619
|
93.62
|
1,387,871
|
6.38
|
3,113,479
|
|
Vincent R. Zurawski
|
21,631,619
|
99.30
|
152,871
|
0.70
|
3,113,479
|
Shareholders also reappointed Ernst & Young as auditor of the Corporation and the result is as follows:
|
Shares For
|
For (%)
|
Shares
Withheld
|
Withheld (%)
|
Non-vote
|
|
Auditor appointment
|
24,860,855
|
99.85
|
37,114
|
0.15
|
0
|
The presentation given by Dr. Yves Fradet and Mr. Richard Bordeleau after completion of the formal business portion of the meeting today is available on DiagnoCure's website at www.diagnocure.com through a link on the Investors page; Presentations.
"The Board of directors greatly appreciates the strong support of our shareholders, which was manifested in this vote and which will be of great value as we proceed with the ongoing discussions to improve royalties from PCA3, to out-license our assets and pursue potential strategic merger activities", stated Dr. Yves Fradet, Chairman of the Board and President and Chief Medical Officer of the Corporation.
About DiagnoCure
DiagnoCure (TSX: CUR; OTCQX: DGCRF) is a life sciences corporation that develops and provides molecular and genomic tests to support effective clinical decisions enabling personalized medicine in oncology. Previstage® GCC and the Corporation new multimarker prostate cancer test are currently available for licensing. The Corporation has granted a worldwide exclusive license on the diagnostic applications of PCA3 for the development and commercialization of a prostate cancer test which is now commercialized in Europe under CE mark and approved for commercialization in Canada and the United States. For more information, please visit www.diagnocure.com.
Forwardlooking statements
This release may contain forwardlooking statements that involve known and unknown risks, uncertainties and assumptions that may cause actual results to differ materially from those expected. Forward-looking statements can be identified by the use of the conditional or forward-looking terminology such as "anticipates", "assumes", "believes", "estimates", "expects", "intend", "may", "plans", "projects", "should", "will", or the negative thereof or other variations thereon. Forward-looking statements also include any other statements that do not refer to historical facts. All such forward-looking statements are made pursuant to the "safe-harbour" provisions of applicable Canadian securities laws. By their very nature, forwardlooking statements are based on expectations and assumptions and also involve risks and uncertainties, known and unknown, many of which are beyond DiagnoCure's control. Forward-looking statements are presented for the purpose of assisting investors and others in understanding certain key elements of the Corporation's current objectives, strategic priorities, expectations and plans, and in obtaining a better understanding of the Corporation's business and anticipated operating environment. Readers are cautioned that such information may not be appropriate for other purposes and that they should not place undue reliance on these forwardlooking statements. For instance, any forward-looking statements regarding the outcome of research and development projects, clinical studies and future revenues, including those related to PCP Risk Score are based on management expectations and such outcome may vary materially depending on global political and economic conditions, dependence on collaboration partners, uncertainty of healthcare reimbursement, and marketing and distribution challenges. In addition, the reader is referred to the applicable general risks and uncertainties described in DiagnoCure's most recent Annual Information Form under the heading "Risk Factors". DiagnoCure undertakes no obligation to publicly update or revise any forwardlooking statements contained herein unless required by the applicable securities laws and regulations.
SOURCE DiagnoCure inc.